From: "Jeffrey E." <jeevacation@gmail.com>
To:
Subject: Re:
Date: Fri, 24 Mar 2017 13:50:53 +0000
decreased by , 1 in 70? for double treatment. is it 1-200 for lower IdI. f?
On Fri, Mar 24, 2017 at 9:48 AM, < > wrote:
Strong LDL reduction Data with decreased cardiovascular events
You saved our dear friend TRL
it's really been a great pleasure working with him and you
Good weekend
rs
Rony Shimony, M.D. F.A.C.C.
Associate Professor of Medicine, Cardiology
Icahn School of Medicine at Mount Sinai
Director, Clinical Cardiology
Mount Sinai West
Mount Sinai Heart
425 West 59th Street
9th Floor
New York, NY 10019
Fax
Cell
dictated and sent from an iPhone kindly excuse typos
On Mar 24, 2017, at 7:25 AM, jeffrey E. <jeevacation@gmail.com> wrote:
thanks for the article on evolcumab, it is clear that it reduces the Idl MARKER. much less clear on its role
in reduction of incidents? you were a mensch with tede
please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
EFTA01051446
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation@gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
please note
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to ja@gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA01051447